Aytu BioScience Completes $5.175 Million Private Placement

ENGLEWOOD, Colo., Sept. 2, 2015, OTCQB, AYTU, /PRNewswire/ Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, announced today that it has closed the final tranche of its planned private placement convertible note financing, raising a total of $5.175 million, which includes proceeds from two prior tranches totaling $3.175 million. Josh Disbrow, Chief Executive Officer of Aytu, stated, Proceeds from this private placement are intended to be used to conduct clinical studies for both Zertane® and RedoxSYS™ and for working capital to begin commercializing FDA-approved ProstaScint®, as well as general corporate purposes.  We look forward to continued execution on our clinical and corporate strategy as we build our urology-focused organization. Newbridge Securities Corporation, through LifeTech Capital, acted as sole placement agent for the institutional portion of the offering. The notes offered a


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: